Skip to main content
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. — Investor Relations & Filings

Ticker · PMN ISIN · CA74346M1095 LEI · 5299007HZF79F9IAXI53 US Professional, scientific and technical activities
Open in API
Filings indexed 333 across all filing types
Latest filing 2025-03-31 Capital/Financing Update
Country CA Canada
Listing US PMN

About ProMIS Neurosciences Inc.

https://www.promisneurosciences.com/

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on the discovery and development of selective antibody therapeutics for neurodegenerative and other misfolded protein diseases. The company leverages a proprietary technology platform to design and generate antibodies that selectively target toxic oligomers, which are key drivers of diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA). Its lead product candidate, PMN310, is in clinical development for Alzheimer's disease. The company's approach aims to provide effective treatments while potentially reducing side effects associated with less specific therapies.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a shelf registration on Form S-3. It details an offering of common shares under an At The Market (ATM) Offering Agreement, including information about the offering size, use of proceeds, risk factors, and legal matters. The document is a detailed disclosure related to capital raising activities and amendments to prior prospectuses. It is not an annual or quarterly report, earnings release, management discussion, or any other type of report. It is clearly a capital/financing update describing the terms and conditions of a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2025-03-31 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key section is Item 2.02 "Results of Operations and Financial Condition," which states that the company issued a press release reporting financial results for the year ended December 31, 2024. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The length of the document is 3,274 characters, which is relatively short and consistent with an announcement rather than a full report. According to the "Menu vs Meal" rule, this is an announcement of financial results (press release) rather than the full earnings release or annual report. Therefore, the document should be classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only.
2025-03-31 English
10-K
Annual Report FY 2024
2025-03-31 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates it is a press release about clinical trial progress attached as Exhibit 99.1. The document is short (3660 characters) and primarily serves as an announcement of this press release. There are no financial statements or detailed financial data included. The document explicitly states that the information is not "filed" for certain regulatory purposes and is a press release. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report. Therefore, the best classification is Regulatory Filings (RNS).
2025-02-25 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 14, 2025, reporting the departure of a Chief Operating Officer and termination of the COO position. The content focuses on management changes and severance arrangements. There are no financial statements or detailed financial data presented. The primary subject is the change in senior management personnel. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3431 characters, which is short and focused on a specific event, not a full report. Therefore, the appropriate classification is MANG with high confidence.
2025-02-19 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-14 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.